Entries by nacnkcell

ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies

$21.5 million Series A round led by current investors Acorn Bioventures and ALSHC, joined by new investor Cormorant Asset Management Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability Galway, Ireland and San Diego, USA, 06 January 2022 – ONK Therapeutics, an innovative NK cell therapy […]

ONK Therapeutics’ CSO Prof. M O’Dwyer and his Academic Group Present New Data Showing the Benefit of Knocking Out the Inhibitory Receptor CD96 on Human NK Cells in the Context of Multiple Myeloma at EHA 2021

The checkpoint inhibitor CD96 was shown conclusively to be an inhibitory receptor on human NK cells in the presence of multiple myeloma (MM) cells expressing CD155 CD96 knock out (KO) using CRISPR/Cas9 gene editing enhanced both NK cell cytotoxicity and cytokine release Efficient engineering of NK cells to genetically eliminate inhibitory receptor expression has the potential […]